Isranalytica 2023, theAnnual assembly of the Israel Analytical Chemical Society, offered Clearmind with the chance to garner visibility for its drug candidate MEAI from attendees at oneof the biggest annual analytical chemistry conferences within the world
Tel Aviv, Israel / Vancouver, Canada, Jan. 25, 2023 (GLOBE NEWSWIRE) — Clearmind Drugs Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or the “firm”), a biotech firm centered on discovery and growth of novel psychedelic-derived therapeutics to resolve main under-treated well being issues, at this time introduced that Professor Joseph Tam, D.M.D., Ph.D., who led the pre-clinical trial for its drug candidate MEAI for treating weight problems, introduced the newest outcomes at Isranalytica 2023.
The presentation, titled “The Psychoactive Drug 5-Methoxy-2-aminoindane (MEAI) Ameliorates Weight problems and its Metabolic Issues,“ included knowledge from not too long ago introduced pre-clinical outcomes demonstrating efficacy of Clearmind’s drug candidate MEAI for treating weight problems and metabolic syndrome.
Isranalytica 2023, the Annual Assembly of the Israel Analytical Chemical Society, ranks as one of many world’s largest annual analytical chemistry conferences. Professor Joseph Tam, D.M.D., Ph.D., heads the Weight problems and Metabolism Laboratory, and he’s an Affiliate Professor of Pharmacology on the Hebrew College’s Institute for Drug Analysis. Together with Dr. Saja Baraghithy, Ph.D., he led the pre-clinical trial as a part of Clearmind’s strong collaboration with the Hebrew College and its know-how switch firm Yissum.
“We’re honored that our analysis companion, Professor Joseph Tam, selected to current the promising outcomes of our MEAI-based remedy for weight problems to professionals and medical friends,” mentioned Clearmind’s CEO Dr. Adi Zuloff-Shani. “Certainly one of our targets is to increase the attention to our distinctive remedies among the many scientific and medical neighborhood, as a large community will facilitate our future medical applications.”
About Clearmind Drugs Inc.
Clearmind is a psychedelic pharmaceutical biotech firm centered on the invention and growth of novel psychedelic-derived therapeutics to resolve widespread and underserved well being issues, together with alcohol use dysfunction. Its major goal is to analysis and develop psychedelic-based compounds and try to commercialize them as regulated medicines, meals or dietary supplements.
The corporate’s mental portfolio presently consists of seven patent households. The corporate intends to hunt extra patents for its compounds each time warranted and can stay opportunistic concerning the acquisition of extra mental property to construct its portfolio.
Shares of Clearmind are listed for buying and selling on Nasdaq and the Canadian Securities Change beneath the image “CMND” and the Frankfurt Inventory Change beneath the image “CWY”.
For additional info go to: https://www.clearmindmedicine.com or contact:
Investor Relations
make investments@clearmindmedicine.com
Phone: (604) 260-1566
Normal Inquiries
Data@Clearmindmedicine.com
www.Clearmindmedicine.com
About Yissum
Yissum is the know-how switch firm of The Hebrew College of Jerusalem. Based in 1964, it serves as a bridge between cutting-edge educational analysis and a worldwide neighborhood of entrepreneurs, traders, and trade. Yissum’s mission is to profit society by changing extraordinary improvements and transformational applied sciences into industrial options that tackle our most pressing international challenges. Yissum has registered over 11,000 patents globally; licensed over 1,140 applied sciences and has spun out greater than 200 firms. Yissum’s enterprise companions span the globe and embrace firms equivalent to Boston Scientific, ICL, Intel, Johnson & Johnson, Merck, Novartis and lots of extra. For additional info please go to www.yissum.co.il
FORWARD-LOOKING STATEMENTS:
This press launch accommodates “forward-looking statements” inside the that means of the Personal Securities Litigation Reform Act and different securities legal guidelines. Phrases equivalent to “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and related expressions or variations of such phrases are supposed to determine forward-looking statements. For instance, the Firm is utilizing forward-looking statements when it discusses the outcomes of preclinical trials, conducting future trials, the outcomes of future initiatives, the submission of patent functions and that psychedelic based mostly remedies maintain potential to deal with and supply devoted options for numerous psychological well being situations. Ahead-looking statements usually are not historic information, and are based mostly upon administration’s present expectations, beliefs and projections, a lot of which, by their nature, are inherently unsure. Such expectations, beliefs and projections are expressed in good religion. Nonetheless, there could be no assurance that administration’s expectations, beliefs and projections will likely be achieved, and precise outcomes might differ materially from what’s expressed in or indicated by the forward-looking statements. Ahead-looking statements are topic to dangers and uncertainties that would trigger precise efficiency or outcomes to vary materially from these expressed within the forward-looking statements. For a extra detailed description of the dangers and uncertainties affecting the Firm, reference is made to the Firm’s reviews filed once in a while with the Securities and Change Fee (“SEC”), together with, however not restricted to, the dangers detailed within the Firm’s closing prospectus (registration No. 333-265900) filed with the SEC on November 16, 2022. Ahead-looking statements communicate solely as of the date the statements are made. The Firm assumes no obligation to replace forward-looking statements to mirror precise outcomes, subsequent occasions or circumstances, modifications in assumptions or modifications in different elements affecting forward-looking info besides to the extent required by relevant securities legal guidelines. If the Firm does replace a number of forward-looking statements, no inference needs to be drawn that the Firm will make extra updates with respect thereto or with respect to different forward-looking statements. References and hyperlinks to web sites have been offered as a comfort, and the knowledge contained on such web sites isn’t integrated by reference into this press launch. Clearmind isn’t accountable for the contents of third-party web sites.
